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Control of Established Colon Cancer Xenografts Using a
Novel Humanized Single Chain Antibody-Streptococcal
Superantigen Fusion Protein Targeting the 5T4
Oncofetal Antigen
Kelcey G. Patterson1, Jennifer L. Dixon Pittaro1, Peter S. Bastedo1, David A. Hess3,4,
S. M. Mansour Haeryfar1,2,5, John K. McCormick1,2,5*
1 Department of Microbiology and Immunology, Western University, London, Ontario, Canada, 2 Centre for Human Immunology, Western University, London, Ontario,
Canada, 3 Department of Physiology and Pharmacology, Western University, London Ontario, Canada, 4 Vascular Biology Research Group, Robarts Research Institute,
London, Ontario, Canada, 5 Lawson Health Research Institute, London, Ontario, Canada

Abstract
Superantigens (SAgs) are microbial toxins that cross-link T cell receptors with major histocompatibility class II (MHC-II)
molecules leading to the activation of large numbers of T cells. Herein, we describe the development and preclinical testing
of a novel tumor-targeted SAg (TTS) therapeutic built using the streptococcal pyrogenic exotoxin C (SpeC) SAg and
targeting cancer cells expressing the 5T4 tumor-associated antigen (TAA). To inhibit potentially harmful widespread
immune cell activation, a SpeC mutation within the high-affinity MHC-II binding interface was generated (SpeCD203A) that
demonstrated a pronounced reduction in mitogenic activity, yet this mutant could still induce immune cell-mediated cancer
cell death in vitro. To target 5T4+ cancer cells, we engineered a humanized single chain variable fragment (scFv) antibody to
recognize 5T4 (scFv5T4). Specific targeting of scFv5T4 was verified. SpeCD203A fused to scFv5T4 maintained the ability to
activate and induce immune cell-mediated cytotoxicity of colorectal cancer cells. Using a xenograft model of established
human colon cancer, we demonstrated that the SpeC-based TTS was able to control the growth and spread of large tumors
in vivo. This required both TAA targeting by scFv5T4 and functional SAg activity. These studies lay the foundation for the
development of streptococcal SAgs as ‘next-generation’ TTSs for cancer immunotherapy.
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The ultimate goal of cancer immunotherapy is to harness
immune-mediated mechanisms to specifically target and eradicate
tumor cells. There have been significant efforts to design SAgbased immunotoxins, also known as tumor-targeted superantigens
(TTS), in order to artificially ‘force’ T cells to recognize tumorassociated antigens (TAAs) in a non-HLA-restricted manner. The
initial TTS represented the fusion of a mouse antibody fragment
(Fab) targeting a colorectal cancer antigen, to the wild-type
staphylococcal enterotoxin A (SEA) SAg. In this pioneering work,
the Fab::SEA TTS demonstrated a substantial reduction in tumor
burden and mortality using a B16 mouse metastasis model [17].
Later studies utilized the fusion of a mouse Fab to target the 5T4
oncofetal antigen with a mutated version of SEA (designed to
reduce MHC-II binding) and this resulted in ,95% reduction of
tumor mass in a non-small cell lung cancer (NSCLC) model [18].
Furthermore, combination therapies with TTSs have also shown
promise in preclinical models in conjunction with cytokine
therapies (e.g. IFN-a) [19] and blockade of CTLA-4 [20]. These
and other studies have clearly demonstrated the potential of TTSs
for cancer immunotherapy. Nonetheless, the TTSs have so far

Introduction
Superantigens (SAgs) are microbial toxins that function as
potent T cell activators and are mediators of the toxic shock
syndrome [1]. These molecules function by binding to lateral
surfaces of major histocompatibility class II (MHC-II) molecules
[2–5], while simultaneously engaging germline-encoded regions
within the variable region of the T cell receptor (TCR) b-chain
(Vb) [6–9]. Since there are ,50 functional Vb genes in humans
[10,11], and because different SAgs can often target multiple Vbs
[12], these toxins stimulate a very large percentage of exposed T
cells leading to the subsequent release of pro-inflammatory
cytokines (e.g. IL-2, IFN-c, and TNF-a) [1]. Although SAgs do
not engage MHC I molecules, these toxins do activate both CD4+
and CD8+ T cells [13], and this can subsequently lead to
bystander activation of accessory cells including NK cells [14]. In
specific cases, SAg can also activate unconventional T cell subsets
such as invariant natural killer T (iNKT) cells [15] and cd T cells
[16].
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been built exclusively using members of the SE class of SAg, and
SEs are also agents of staphylococcal food-borne illness, an activity
that is thought to be independent of the ability to activate T cells
[21]. Although manageable, some of the side effects seen in TTS
Phase I and Phase II clinical trials included nausea, vomiting and
diarrhea [22–24], and may have been related to the emetic
properties of SEA [25]. Additionally, many patients had preexisting antibodies to SEA which required individualized TTS
dosing [26]. In order to reduce the antigenicity of the TTS
therapeutic, anti-5T4 Fab was linked to an engineered SEA/SEE
fusion (called Naptumomab estafenatox; ABR-217620) [27]. This
latest TTS therapeutic has undergone a Phase I clinical trial as a
monotherapy in patients with advanced NSCLC, pancreatic
cancer and renal cell carcinoma (RCC), and as a combination
therapy with Docetaxel in patients with NSCLC, demonstrating
that ABR-217620 was well tolerated with some evidence of antitumor activity [24]. Early information from a recently completed
Phase II/III trial with ABR-217620 in patients with RCC
comparing ABR-217620 and interferon-a, to interferon-a alone,
did not reach the primary endpoint of overall survival; however, it
appears that many patients had higher than expected baseline
levels of anti-SEA/SEE antibodies, which may have contributed to
suboptimal therapy [28].
Bacterial genomic sequencing efforts over the last decade have
now revealed an extensive ‘family’ of SAg exotoxins in both
Staphylococcus aureus and Streptococcus pyogenes. A general feature of
these toxins is that genetically distinct SAgs are also antigenically
distinct, and furthermore, distinct SAgs also typically display
unique Vb activation profiles [12]. Thus, S. aureus and S. pyogenes
have provided an abundance of T cell mitogens that could
potentially be engineered as TTSs for cancer therapy. In the
current work, we sought to expand the repertoire of TTSs to
include the first streptococcal SAg using streptococcal pyrogenic
exotoxin C (SpeC) as the prototype. A potential advantage of
engineering a streptococcal SAg as a TTS is that these toxins lack
bona fide emetic activity [29], which may result in fewer side
effects. Also, SpeC is very well studied in terms of both structure
[4,30,31] and function [9,32–35] for engagement of host
receptors, providing a platform for tailoring activity. Herein, we
demonstrate that SpeC mutagenized within the zinc-dependent,
high-affinity MHC-II binding domain (SpeCD203A) has reduced
superantigenicity while retaining tumoricidal properties. We
generated a SpeCD203A-based TTS fusion protein using an
engineered human scFv that specifically targets human 5T4
(scFv5T4). In a humanized mouse model of colon cancer, we
demonstrate that the scFv5T4::SpeCD203A TTS controls the
growth and metastatic potential of an established colon cancer
tumor, and that this anti-tumor activity requires both specific
targeting by the scFv5T4 moiety, as well as SAg function.

Antibodies and dyes
The following monoclonal antibodies and dyes were used: PE
anti-human CD4 (clone RPA-T4; BD Pharmingen); AlexaFluor700 anti-human CD8 (clone RPA-T8; BD Pharmingen);
APC anti-human CD3 (Clone UCHT1; BD Pharmingen);
CellTrace CFSE (carboxyfluorescein diacetate; Molecular Probes);
7-AAD (7-aminoactinomycin D; Molecular Probes); anti-human
5T4 (ab88091; Abcam); IgG2b isotype (eBioscience); FITC antimouse IgG (eBioscience); strepativdin-IRDye800 (Rockland Immunochemicals); streptavidin-FITC (Rockland Immunochemicals).

Bacterial strains
Escherichia coli XL1-Blue (Stratagene) or DH5a (Invitrogen) were
used for cloning purposes and E. coli BL21 (DE3) (Novagen) was
used as the protein expression host. E. coli strains were grown
aerobically at 37uC in Luria broth (LB) containing kanamycin
(50 mg/ml), ampicillin (200 mg/ml) or chloramphenicol (10 mg/ml)
to maintain plasmids.

Cloning procedures
Plasmid constructs were either previously published [34,35] or
generated by standard cloning techniques [36], in either pET-41a
(Novagen) or pET-32a (Novagen) and are summarized in Table
S1. All plasmid inserts were sequenced at the Robarts Research
Institute Sequencing Facility (London, Ontario, Canada). Protein
expression clones in pET-32a or pET-41a were altered such that
the enterokinase cleavage site (DDDDKQX) was replaced with a
Tobacco Etch Virus (TEV) protease cleavage site (ENLYFQQS).
Transfection vectors pCMV6-XL5, pCMV6-XL5::5T4 and
pEGFP-N1 were purchased from Origene Technologies, and
Clonetech Laboratories, respectively. All other transfection
plasmids were generated by standard cloning techniques. The
murine scFv5T4 cDNA [37] was recoded and then manufactured
by GenScript Inc. to generate a humanized sequence. Amino acid
substitutions were made in the backbone sequence of scFv5T4
from the original mouse scFv sequence, determined by aligning
with a human consensus sequence. The CDR loops specific for
5T4 [37], and the immediate amino acids flanking the predicted
loops were not altered to maintain antibody specificity.

Protein expression
Recombinant proteins were produced using an E. coli BL21
(DE3) expression system containing the pBirACm plasmid. Cells
were grown aerobically at 37uC in LB medium to OD600 = 0.5 and
protein expression was induced overnight (18–24 h) at room
temperature (RT) with 0.2 mM isopropyl-D-thiogalactopyranoside (IPTG; BioBasic Inc.) and biotinylated with the addition of
50 mM D-biotin (BioBasic Inc.). Cells were pelleted at 4uC and
resuspended in cold 20 mM Tris-HCl, pH 7.4, 200 mM NaCl
containing 0.25 mg/ml lysozyme (Sigma-Aldrich) and 0.02 mg/
ml DNase I (Sigma-Aldrich). Cells were incubated on ice for 1 h
prior to lysis with a continuous head flow cell disruptor (Constant
Systems Ltd.) at 25 psi, followed by sonication with output 4,
1 pulse/ml. Cellular debris was pelleted at 4uC at 100006g.
Supernatants were applied to a charged Ni-NTA affinity column
(Novagen) and increasing concentration of imidazole was used to
elute the purified protein. Purified fractions were dialyzed 36
against 20 mM Tris-HCl, pH 7.4, 200 mM NaCl buffer and the
N-terminal tags were cleaved by autoinactivation-resistant His7::TEV [38], as described [39]. Cleaved proteins were applied and
eluted from a second Ni-NTA affinity column to remove TEV
protease and obtain a pure protein. Proteins were dialyzed 36

Materials and Methods
Ethics statements
Experiments using primary human lymphocytes were reviewed
and approved by Western University’s Research Ethics Board for
Health Sciences Research Involving Human Subjects. Informed
written consent was obtained from all blood donors. All animal
experiments were in accordance with the Canadian Council on
Animal Care Guide to the Care and Use of Experimental Animals,
and the protocol was approved by the Animal Use Subcommittee
at Western University (London, Ontario).
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against 20 mM Tris-HCl, pH 7.4, 200 mM NaCl buffer or 0.9%
NaCl (saline) and assessed for homogeneity by SDS-PAGE and
quantified (BCA Protein Assay, Pierce).

Cytotoxicity assays
Two assays were used to measure the ability of the various
proteins to induce PBMC-mediated killing of cancer cells. First, in
vitro killing was evaluated by co-culturing human PBMCs with
either WiDr cells or HT-29 at a ratio of 10:1 and titrating SAgs
including SpeCWT, SpeCY15A, SpeCD203A, or SpeCY15A/D203A for
48 h. Cells were labeled with 7-AAD following the manufacturer’s
protocol and analyzed by FACS (BD Canto II). Using FlowJo
software, the WiDr or HT-29 populations were gated upon by
comparison of human PBMC alone samples and subsequently
assessed for presence or absence of 7-AAD. Second, human
PBMCs were treated with SAg, scFv5T4 or fusion proteins as in
the FACS assay for 48 h in a U-bottom microtitre plate (BD
Biosciences). Target HT-29 cells were labeled with (Na)251CrO4
(Perkin Elmer Inc.) in cRPMI. PBMCs were added at effector:target cell ratios of either 1:1, 5:1 or 10:1 against HT-29.
Cytotoxicity was measured after 4–6 h incubation at 37uC with
5% CO2 in a standard chromium release assay measuring the 51Cr
content of culture supernatants using a gamma-counter (Wallac
Wizard 1470 Automatic Counter). Total release control was
obtained by exposing target cells to 1% sodium dodecyl sulfate
(EMD Millipore). The specific lysis was calculated according to the
formula:

Cell lines
Human colorectal adenocarcinoma cell lines (HT-29 and WiDr)
were cultured in complete Dulbecco’s Modified Eagle Medium
(cDMEM; Gibco) and HEK293 cells were cultured in complete
Minimum Essential Media (cMEM; Gibco). All culture media
were supplemented with 10% fetal bovine serum (FBS; SigmaAldrich), 10 mM HEPES, pH 7.4 (Gibco), 2 mM L-Glutamine
(Gibco), 1 mM sodium pyruvate (Gibco), 100 mM non-essential
amino acids (Gibco), 100 mg/ml streptomycin (Gibco), and
100 U/ml penicillin (Gibco).

scFv5T4 specificity assays
HEK293 cells (16105) were seeded into 24-well plates (Corning)
with 500 ml cMEM and allowed to grow overnight (24 h) at 37uC
with 5% CO2. Liposome:DNA complexes were formed using
Lipofectamine2000 (Invitrogen) and plasmid DNA of choice as per
the manufacture’s protocol. Complexes were formed in cMEM
without FBS or antibiotics. Transfection of cells occurred in the
same media for 4 h at 37uC with 5% CO2, after which the media
was removed and replaced with cMEM for plasmid expression
over 24 h. Once expressed, scFv5T4::mRFP1 (1:100; 2 mg/ml)
was incubated with the cells for 1 h at RT and subsequently
washed and viewed with fluorescence microscopy using an
Olympus IX71 fluorescent microscope. Alternatively, transfected
HEK293 cells (as above) or HT-29 cells (1.06106) were incubated
for 1 h with mAb5T4 (1:200) or scFv5T4-biotin (1:100; 2 mg/ml),
followed by anti-mouse IgG-FITC (1:1000) or streptavidin-FITC
(1:1000), respectively, for 1 h at 4uC and viewed with fluorescence
microscopy or FACS (BD FACSCanto II), respectively. Microscopy images were taken using ImagePro Plus Software, and FACS
analysis was completed using Flowjo Software.

% specific lysis
~

Evaluation of tumor burden and metastases
Immunodeficient NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG)
mice were bred in an animal barrier facility, and housed under
sterile conditions with food and water ad libitum. Based on a
previously developed protocol [18,40], 13-week old mice were
injected intraperitoneally with 36106 HT-29 cells in 0.2 mL
vehicle (PBS). Three weeks later, after tumors were palpable, the
mice were injected intraperitoneally with either vehicle alone
(n = 3) or 16106 human PBMCs in 0.2 mL vehicle (n = 20).
PBMC-treated mice were grouped (n = 4) with a random number
generator to receive either scFv5T4::SpeCD203A, or controls
SpeCD203A, scFv5T4, scFv5T4::SpeCY15A/D203A, or vehicle alone.
Two hours after receiving PBMCs, 2 mM/kg of treatment,
controls, or vehicle alone was injected intravenously. Mice with
no PBMCs received vehicle alone. Intravenous treatment injections were given daily for 7 additional days. After 4 weeks, the
mice were sacrificed and the total tumor volume was determined.
The mice were also examined visually for macro-metastases and
scored accordingly based on the degree of regional spread distant
from the primary tumor site. All tumors were excised, size- and
weight-measured in a blinded fashion.

Proliferation assays
Human peripheral blood mononuclear cells (PBMCs) were
prepared from the whole blood of healthy donors and isolated by
density centrifugation over Ficoll-Paque Plus (GE Healthcare Life
Sciences). Human lymphocytes were cultured in RPMI-1640
(Gibco) with 10% FBS and supplemented as above (cRPMI). All
tissue culture cells were maintained at 37uC with 5% CO2.
Human PBMCs were labeled with CellTrace CFSE (Molecular
Probes) as per manufacturer’s instructions. Cells (0.86106–
1.06106) were cultured in cRPMI containing 2 mg/ml Polymyxin
B (ICN Biomedicals Inc.) and treated with either wild-type SpeC
(SpeCWT) or variants SpeCY15A, SpeCD203A or SpeCY15A/D203A
(1 mg/ml) and incubated for 5 days at 37uC with 5% CO2. Cells
were then washed and stained with anti-human CD3 (1:200), antihuman CD4 (1:200) and anti-human CD8 (1:200) antibodies for
30 min on ice and analyzed by FACS (BD Canto II), using FlowJo
software. For radioactive proliferation assays, human PBMCs
(2.06105) were cultured in cRPMI containing 2 mg/ml Polymyxin
B (ICN Biomedicals Inc.) with titrating SpeC variants, scFv5T4,
scFv5T4::SpeCD203A or scFv5T4::SpeCY15A/D203A in U-bottom
96-well microtitre plates (BD Biosciences). Cells were incubated
for 72 h and subsequently labeled with 3H-thymidine (Perkin
Elmer Inc.) for 18 h at 37uC with 5% CO2. Cells were harvested
onto glass-fibre filters and DNA-incorporated 3H-thymidine was
measured in a beta scintillation counter (Wallac 1450 Microbeta
Counter).

PLOS ONE | www.plosone.org

experimental release spontaneous release
x100
total release spontaneous release

Statistical analysis
Statistical comparisons were performed using an unpaired
Student t test or by 2-way ANOVA with Bonferroni multiple
comparison test (GraphPad Prism). Differences were considered
significant when p,0.05.

Results
Generation of a SpeC-based TTS
SpeC is a potent and well-characterized streptococcal SAg
known to target primarily Vb2+ human T cells [32] which
3
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Figure 1. Overview of the SpeC-mediated T cell activation complex and mutations to reduce systemic toxicity. A) Structural overview
of SpeC in complex with TCR and MHC-II. TCR Va chain is colored orange, TCR Vb chain is colored grey, MHCa-chains are colored red, MHCb-chains
are colored green, antigenic peptides are colored black, and the zinc atom is colored magenta. SpeC is colored blue with important interface residues
Y15 and D203 highlighted in yellow. The ternary model of TCR-SpeC-(MHC)2 was produced as described previously [9] and the ribbon diagram was
generated using PyMOL (http://www.pymol.org). B) Proliferation of human PBMCs mediated by SpeCWT or proteins containing mutated residues
Y15A (TCR-binding mutant), D203A (MHC-II-binding mutant) or Y15A/D203A was determined by the uptake of 3H-thymidine after 72 h poststimulation (n = 5 in triplicate; data representative of one individual). C) Dose-dependent cytotoxicity of 7-AAD+ WiDr cells after 48 h incubation with
human PBMCs and either SpeCWT, SpeCY15A, SpeCD203A, or SpeCY15A/D203A (n = 3–6 per group). (D–E) Proliferation of CFSE labeled-human PBMCs
mediated by SpeCWT or proteins containing mutated residues was determined by FACS five days post-stimulation, specifically measuring total CD3+ T
cell population, CD3+CD4+ T cells and, CD3+CD8+ T cells (n = 4; FACS data representative of one individual).
doi:10.1371/journal.pone.0095200.g001

represent ,7% of the approximately 25 million distinct TCRs
[41]. Prior work indicates that Tyr15 is a critical residue for this
SAg to engage the TCR [34], and Asp203 is necessary to coordinate a zinc-mediated high-affinity interface with the b-chain of
MHC-II [4,35,42] (Figure 1A). Indeed, the single Asp203RAla
mutation in SpeC has been demonstrated to dramatically reduce
toxicity in a lethal model of toxic shock syndrome [42]. We first
evaluated the ability of wild-type SpeC (SpeCWT), SpeCY15A,
SpeCD203A, and SpeCY15A/D203A to activate human PBMCs and
induce PBMC-mediated killing of cancer cells. Both SpeCY15A and
SpeCD203A were impaired for the ability to expand PBMCS by
,100-fold compared with SpeCWT, and the SpeCY15A/D203A
double mutant was unable to induce PBMC proliferation
(Figure 1B). Next, PBMC-dependent killing of the human
colorectal cancer cell line WiDr was evaluated. SpeCY15A caused
PLOS ONE | www.plosone.org

a significant reduction in WiDr cytotoxicity compared with
SpeCWT, and both the SpeCD203A and SpeCY15A/D203A mutants
failed to induce WiDr cytotoxicity (Figure 1C). We also assessed
the ability of the recombinant proteins to specifically induce
proliferation of human CD3+CD4+ and CD3+CD8+ T cell
populations at 1 mg/ml. SpeCWT and each of the single mutants
were able to induce proliferation of both subsets, while the double
mutant failed to induce proliferation of either subset (Figure 1D
and 1E). These data indicate that TCR and MHC-II engagement
are important for induction of immune cell-mediated killing by
SpeCWT, and that SpeCD203A may be a suitable mutant to reduce
or prevent systemic immune cell activation while maintaining full
engagement with the TCR.
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Figure 2. Specific targeting of scFv5T4. A) Histograms demonstrating surface binding of the indicated antibodies, either commercial mAb5T4 or
generated scFv5T4 (empty curves), to 5T4 TAA on colorectal cancer cell line HT-29 measured by FACS. The shaded curves show the IgG2b isotype
control (top panel) or streptavidin-FITC alone (bottom panel). B) Visualization of commercial mAb5T4, or scFv5T4, targeting of HEK293 cells
transfected with empty vector (pCMV6-XL5) or pCMV6-XL5::5T4 by fluorescence microscopy. Representative images taken at 4006 magnification. C)
Visualization of HEK293 transfected with pEGFP-N1 or pEGFP-N1::5T4 and incubated with scFv5T4::mRFP1. Same field of view photographs were
taken under phase contrast, and green and red fluorescent filters at 1006 magnification.
doi:10.1371/journal.pone.0095200.g002

HEK293 cells that contain only the vector did not stain with either
antibody (Figure 2B). scFv5T4 specificity for 5T4 was also
determined by incubation of scFv5T4::mRFP1 with HEK293 cells
transfected with pEGFP-N1::5T4, or control vector pEGFP-N1.
Microscopic analysis of GFP::5T4-expressing HEK293 cells
demonstrated that scFv5T4 bound only to those cells expressing
the 5T4::GFP fusion, but not to control transfected cells
(Figure 2C). Together, these data indicate that the humanized
scFv5T4 can bind specifically to human 5T4.

Engineered human scFv5T4 specifically targets the 5T4
tumor-associated antigen
In order to develop a specific targeting mechanism for
SpeCD203A, we generated a humanized scFv based on the
complementarity determining regions (CDRs) of the characterized
mouse scFv specific for the human 5T4 TAA [37]. The cDNA
sequence was designed to incorporate a ‘humanized’ backbone
sequence, with the CDRs remaining specific for human 5T4.
Amino acid substitutions were determined by aligning the
previously described mouse scFv5T4 with 10 human scFv
sequences generating a consensus sequence. This cDNA sequence
was codon optimized for E. coli and synthesized, and was
subsequently used for the generation of a number of recombinant
proteins (Table S1).
To first examine the specificity of the humanized scFv5T4 for
binding to human 5T4, the scFv5T4 cDNA was engineered to
contain a C-terminal biotin tag, or genetically fused to monomeric
red fluorescent protein 1 (mRFP1) [43]. Upon incubation with the
human HT-29 colorectal cancer cells known to express 5T4 [44],
from which WiDr cells are derived [45], scFv5T4 bound to the
surface of these cells comparably to commercial anti-human 5T4
mAb (Figure 2A). HEK293 cells engineered to express the 5T4
antigen bound both the mAb5T4 as well as the scFv5T4 fragment
as shown by immunofluorescence microscopy, whereas control
PLOS ONE | www.plosone.org

Generation of scFv5T4::SpeCD203A
In order to target SpeC to 5T4, SpeC was translationally fused
to scFv5T4 and recombinant scFv5T4::SpeCD203A was expressed
from E. coli BL21(DE3) and purified (Figure 3). In addition,
control reagents were generated including scFv5T4 alone, and a
non-functional fusion protein containing SpeCY15A/D203A, each as
soluble proteins containing C-terminal biotin tags (Figure 3).

Human T-cell proliferation and cytotoxicity induced by
scFv5T4::SpeCD203A
We first tested scFv5T4::SpeCD203A and the control proteins for
the ability to proliferate induced human PBMCs.
scFv5T4::SpeCD203A induced a dose-dependent proliferative

5
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Immunotherapy of established colon cancer using
scFv5T4::SpeCD203A

SpeC is specific for human Vb2+ T cells, but this SAg does not
recognize mouse T cells [32]. Thus, testing the SpeC-based TTS
required a model utilizing human lymphocytes. Furthermore, the
human 5T4 targeting scFv has minimal cross-reactivity with
murine 5T4 [37]. Therefore, human tumor cells expressing
human 5T4 were necessary for the experiments. Based on a
previously developed model [18,40], we employed immunodeficient NOD SCID IL2Rc2/2 (NSG) mice for the engraftment of
5T4+ human HT-29 colorectal adenocarcinoma cells. NSG mice
lack T, B and NK cells [46] and represent an optimum mouse
strain for human tumor engraftment [47]. Furthermore, these
mice permit the survival of transferred human immune cells
[46,48]. HT-29 cells were injected intraperitoneally into NSG
mice and once solid tumors were palpable (at 3 weeks postinjection), treatments were initiated with intraperitoneal injection
of human PBMCs, followed by 8 daily intravenous injections of
scFv5T4::SpeCD203A (Figure 5A). Control NSG mice did not
receive PBMCs, or received PBMCs without additional treatments. Additional groups included the scFv5T4 alone, SpeCD203A
alone, or inactive scFv5T4::SpeCY15A/D203A. Tumor surface area
was monitored using caliper measurement throughout the
experiment and demonstrated little to no growth of the tumors
in the scFv5T4::SpeCD203A treatment group, while growth was
observed in all other groups (Figure 5B). Mice were sacrificed at
week 8 of the experiment and tumors were evaluated in a blinded
fashion. This experiment demonstrated a dramatic reduction in
the total tumor volume after treatment with scFv5T4::SpeCD203A
that was significantly different from mice that did not received
PBMCs, sham treated mice (saline), and mice treated SpeCD203A
or scFv5T4::SpeCY15A/D203A (Figure 5C). Importantly, the
scFv5T4::SpeCD203A treatment group also demonstrated a significant reduction in the total metastases score compared with all
other groups (Figure 5D and 5E). There were no differences in
tumor volumes or number of metastases between mice that did not
receive PBMCs and the different control reagents (Figure 5D).

Figure 3. Generation of the scFv5T4::SpeCD203A fusion protein
and control reagents. A) Schematic illustration representing the
components of the generated fusion protein constructs. The protein
consists of the generated 5T4-targeted humanized single chain variable
fragments, VH and VL (grey bar), genetically fused to streptococcal
superantigen SpeC (blue bar) either containing an alanine substitution
at residue D203 or an additional alanine substitution at residue Y15. All
constructs were generated to contain a C-terminal biotin tag. The
purified recombinant proteins are shown by SDS-PAGE (panel B), and
detected by Western blot analysis by streptavidin-IRDye800 (panel C).
doi:10.1371/journal.pone.0095200.g003

response of human lymphocytes that was comparable to
SpeCD203A (Figure 4A). Importantly, the scFv5T4 antibody
fragment alone and the double mutant fusion (scFv5T4::SpeCY15A/D203A) did not induce significant proliferative responses.
This indicates that the SpeCD203A portion of the fusion is
responsible for inducing PBMC activation. The immunotherapeutic agent was then evaluated for the ability to mediate tumor
cell killing by human SpeC-reactive PBMCs in two assays. First,
the human colorectal cancer cell line WiDr was used as the target
in a 7-AAD-based killing assay. Efficient cell killing was observed
after human PBMCs were stimulated with 200 nM of the agent for
48 hours, compared to wild-type SpeC and unstimulated controls
(Figure 4B). Second, HT-29 cells labeled with 51Cr were used as
targets. Efficient cell killing was observed in a dose-dependent
manner after human PBMCs were stimulated with the agent for
48 hours, and subsequently added to tumor cells with increasing
effector to target (E:T) ratios (Figure 4C). Furthermore, the single
mutant fusion (scFv5T4::SpeCD203A) was more efficient than that
of the similar double mutant fusion (scFv5T4::SpeCY15A/D203A) or
antibody alone, but was reduced when compared with SpeCWT.
These data indicate that scFv5T4::SpeCD203A is functional for
inducing immune cell-mediated cancer cell death and that
SpeCD203A, scFv5T4, and scFv5T4::SpeCY15A/D203A proteins
can function as precise controls to evaluate the requirement for
targeting and SAg activity in vivo.

PLOS ONE | www.plosone.org

Discussion
T lymphocytes are recognized as one of the most important
immune cells involved in tumor regression in cancer immunotherapy, and bacterial SAgs are among the most potent naturally
occurring specific activators of T cells. Thus, the appropriation of
SAgs to target cancer cells [17] has received significant attention,
and TTS therapeutics have now been evaluated in human clinical
trials [22–24,26,49,50].
In the current study, we describe the development of a ‘‘next
generation’’ TTS composed of the streptococcal T cell activating
toxin SpeC and a humanized scFv targeting the 5T4 TAA. In this
work, we focused on colorectal cancer as this carcinoma is difficult
to diagnose with few symptoms until the onset of stage III or IV,
and ,20% of patients will present with inoperable colorectal
cancer [51]. The expression of the 5T4 TAA is restricted on
normal adult tissues but is found on an array of carcinomas [52]
and has been associated with metastasis in colorectal cancer [53].
This work provides further preclinical evidence for 5T4 as a
potential TAA for targeted colorectal cancer immunotherapy, and
that TTSs may be useful to inhibit or prevent further metastatic
disease. As monoclonal antibodies that target vascular endothelial
growth factor (VEGF) (e.g. Bevacizumab) and epidermal growth
factor receptor (EGFR) (e.g. Cetuximab or Panitumumab) have
shown benefit in patients with metastatic colorectal cancer [54–
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Figure 4. Functionality of SpeC mutants and fusion proteins for human PBMC proliferation and cytotoxicity in vitro. A) SpeC proteins
were used to compare scFv5T4 alone, scFv5T4::SpeCY15A/D203A and subsequently scFv5T4::SpeCD203A in the uptake of 3H-thymidine as a measure of
PBMC proliferation after 4 day incubation (n = 5). B–C) Dose-dependent SpeC-mediated PBMC cytotoxicity of scFv5T4::SpeCD203A was determined by
comparing SpeC controls, scFv5T4 alone and scFv5T4::SpeCY15A/D203A after 48 h incubation by using FACS analysis of WiDr (panel B), measuring
percent cancer cell death with 7AAD-exclusion staining (n = 3) and 51Cr-release to measure the specific cytotoxic potential (panel C) when incubated
with increasing effector:target ratios and 51Cr-labeled HT-29 cancer cells. Data shown (mean 6SEM) is from four independent human donors each
done in triplicate. *p,0.05, ***p,0.001, compared to the inactive SpeCY15A/D203A control protein.
doi:10.1371/journal.pone.0095200.g004

There are some potential advantages, and disadvantages, in
using TTSs for tumor immunotherapy that require further
consideration. The use of a mouse derived antibody as a targeting
motif may result in human anti-mouse antibody (HAMA)
responses since murine mAbs are highly immunogenic [58]. This
may limit the utility of subsequent treatments and thus the use of a
humanized scFv containing TTS as developed in this work may
provide clinical benefit. Second, bacterial SAgs are produced by
bacteria that are often frequent colonizers in humans and thus
many individuals will have pre-existing and neutralizing antibodies
to many streptococcal and staphylococcal SAgs [59,60]. To
overcome this issue, we foresee the future generation of
‘combinatorial’ TTSs with different SAgs such that individual
patients could be screened for SAg neutralizing antibodies and
then treated with an appropriate TTS. Early work in this area
demonstrated that multiple SEs are capable of inducing T cellmediated cytotoxicity against cancer cells [61]; however, we
envision the SAg panel would include members from the Group
IV and Group V subclass of SAgs [1,39,62], as these subclasses
contain only streptococcal SAgs and staphylococcal enterotoxinlike (SEl) SAgs, that collectively lack the emetic properties of the
bona fide SEs [62]. Indeed, the SEl-M, SEl-N and SEl-O SAgs
from the staphylococcal ‘enterotoxin gene cluster’ (egc) have
recently been demonstrated to induce T cell dependent killing of
a broad panel of human tumor cells in vitro [63]. Also, human

56], a future area of interest would be to evaluate TTS
combination therapies with these more established treatments.
This work demonstrated that the soluble recombinant fusion
protein scFv5T4::SpeCD203A was able to specifically target 5T4 to
elicit a T cell response that substantially reduced tumor burden in
vivo. Importantly, we used a model of large and established tumors
in order to robustly test the SpeC-based TTS. Although the
tumors did not appear to regress, the data clearly demonstrates
that scFv5T4::SpeCD203A was able to prevent further tumor
growth as well as the development of peritoneal metastases. As
scFv5T4::SpeCD203A and SpeCD203A showed similar activity in
vitro (Figure 4a), the inability of SpeCD203A to impact tumor size
or metastatic disease indicates that the scFv5T4 moiety of the
fusion protein was required for in vivo targeting of 5T4+ HT-29
cells (Figures 2A, 5C and 5D). Likewise, the inability of scFv5T4
alone, or the inactive scFv5T4::SpeCY15A/D203A fusion to show
any measurable impact (Figure 5C and 5D) demonstrates that T
cell-dependent SAg activity was also required for tumor cell killing.
Although the SpeCD203A mutant was designed to reduce systemic
T cell activation, the mouse Fab moiety in the 5T4Fab-SEA/E120 TTS has been shown to effectively replace the MHC-II
binding domain such that T cells are efficiently activated when
artificially ‘presented’ by the tumor [57]. We suspect that the
humanized scFv5T4 moiety here played a similar role contributing
to the dramatic reduction in tumor volume and metastatic disease.
PLOS ONE | www.plosone.org
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Figure 5. SpeC-based TTS therapy of established HT-29 colon cancer. A) Schematic illustration of the xenograft solid tumor model
experimental timeline. NSG mice with established (3 week) intraperitoneal human HT-29 tumors were injected once with human PBMC
intraperitoneally, followed by 8 daily intravenous injections of scFv5T4::SpeCD203A, or individual controls (2 mM/kg/injection). B) Primary tumor size
was evaluated throughout the experimental timeline by external caliper measurements. Twenty-eight days post-final injection, final tumor volume
was measured (panel C) and metastatic score (panel D) evaluated. All groups contained n = 4, with exception of saline alone control (n = 3). *p,0.05,
**p,0.005. Gross pathology and metastases in representative NSG mice with HT-29 tumors treated with scFv5T4::SpeCY15A/D203A or
scFv5T4::SpeCD203A. The primary tumor is labeled with a triangle and metastases are labeled with arrows.
doi:10.1371/journal.pone.0095200.g005

serum levels of neutralizing antibodies against the egc SEs have
been shown to be lower than those directed against the ‘classic’
SEs [64]. In addition, each of the Group IV and V SAgs have a
well defined zinc-binding motif [1] involved in high-affinity MHCII binding [4,5] that can be targeted for appropriate mutagenesis
to prevent systemic immune activation as shown here and
previously for SEA [65]. A third important limitation to TTS
immunotherapy is that bacterial SAgs are well known to induce
Vb-specific T cell deletion or anergy [66], which includes CD8+ T
cells [67]. Thus, repeated administration of the same TTS in
humans may result in populations of non-responsive T cells.
However, using the B16 model of melanoma, a sufficient resting
period between treatments did restore immune responsiveness
resulting in prolonged survival with repeated cycles of therapy
[68]. Nevertheless, this limitation could potentially be circumvented by the use of multiple SAgs with different Vb profiles. A
remaining and important issue with TTS immunotherapy is the
targeting of a single TAA. An effective TTS would likely invoke a
form of cancer immunoediting [69], and simple down regulation
of the TAA may provide a means of escape. The TTS
immunotherapy platform offers an approach for targeting a
number of different TAAs, and it will be of future interest to
engineer and combine TTSs that utilize SAgs with different Vb
profiles.
Immunotherapies such as the chimeric antigen receptors
(CARs) targeting CD19 have now demonstrated some extraordi-

PLOS ONE | www.plosone.org

nary clinical outcomes in patients with advanced B cell leukemia
[70–73]. In addition, blocking immune system regulatory checkpoints with antibodies (e.g. anti-CTLA-4 or anti-PD-1) is
providing additional avenues for cancer immunotherapy [74].
TTSs may represent a additional ‘off-the-shelf’ therapy to harness
Vb-specific T cell subsets without the requirement for manipulation of autologous T cells. This work may help to guide the ‘next
generation’ of TTSs for tailored cancer immunotherapy.
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